Trial Profile
Long term efficacy and safety of omalizumab in patients with Eosinophilic granulomatosis with polyangiitis and asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2016
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma; Granulomatosis
- Focus Adverse reactions; Therapeutic Use
- 04 Oct 2016 New trial record